Kevin Bitterman, an insider at Disc Medicine Inc (IRON), acquired 7,000 shares of the company on December 14, 2025, at a price of $13.50 per share, totaling $95,000. Following this transaction, Bitterman holds 7,000 shares of Disc Medicine.
Disc Medicine, headquartered in Watertown, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing treatments for hematologic diseases. The firm has a market capitalization of $3.5 billion and reported an earnings per share (EPS) of -5.35 for the trailing twelve months. The company's pipeline includes treatments for conditions such as erythropoietic porphyrias and Diamond-Blackfan Anemia, with notable candidates including bitopertin and DISC-3405.
Insider purchases are often seen as a positive signal, as executives typically have access to non-public information regarding their company's performance. However, it is essential for investors to consider insider transactions alongside broader market trends and other relevant factors.
Upcoming earnings for Disc Medicine are scheduled for May 5, 2026, with an estimated EPS of -1.80 and revenue of $1.4 million, followed by another report on August 5, 2026, projecting an EPS of -1.64 and revenue of $5.7 million.